| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
33,511,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile MiNK Therapeutics is a clinical stage biopharmaceutical company engaged in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Co.'s key product candidate, AGENT-797, is an off-the-shelf, allogeneic iNKT cell therapy. In addition, Co. is developing a pipeline of allogeneic iNKT programs. Co.'s key programs include a CAR-iNKT program targeting B-cell maturation antigen (BCMA), which it refers to as BCMA-CAR-iNKT, and a tumor stromal targeting CAR-iNKT program, which it refers to as stromal target-CAR-iNKT. These programs are both in preclinical development.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
250,706 |
666,494 |
| Total Buy Value |
$0 |
$0 |
$368,144 |
$817,474 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
7 |
15 |
| Total Shares Sold |
0 |
0 |
0 |
100,000 |
| Total Sell Value |
$0 |
$0 |
$0 |
$94,850 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wiinberg Ulf |
Director |
– • – |
2023-06-01 |
4 |
A |
$1.76 |
$14,001 |
D/D |
7,955 |
50,706 |
|
- |
|
| Ryan Barbara |
Director |
– • – |
2023-06-01 |
4 |
A |
$1.76 |
$17,751 |
D/D |
10,086 |
38,930 |
|
- |
|
| Behner Peter |
Director |
– • – |
2023-06-01 |
4 |
A |
$1.76 |
$15,375 |
D/D |
8,736 |
33,721 |
|
- |
|
| Corvese Brian |
Director |
– • – |
2023-06-01 |
4 |
A |
$1.76 |
$17,876 |
D/D |
10,157 |
317,505 |
|
- |
|
| Baldoni John |
Director |
– • – |
2023-06-01 |
4 |
A |
$1.76 |
$14,376 |
D/D |
8,168 |
31,528 |
|
- |
|
| Agenus Inc |
|
– – • |
2023-05-11 |
4 |
B |
$1.43 |
$33,348 |
D/D |
23,361 |
21,640,473 |
0.01 |
- |
|
| Agenus Inc |
|
– – • |
2023-05-10 |
4 |
B |
$1.51 |
$33,296 |
D/D |
22,065 |
21,617,112 |
0.01 |
- |
|
| Agenus Inc |
|
– – • |
2023-05-05 |
4 |
B |
$0.95 |
$95,100 |
D/D |
100,200 |
21,595,047 |
0.01 |
- |
|
| Armen Garo H |
|
– • – |
2023-05-05 |
4 |
S |
$0.95 |
$94,850 |
D/D |
(100,000) |
1,866,400 |
|
- |
|
| Agenus Inc |
|
– – • |
2023-05-04 |
4 |
B |
$1.22 |
$26,246 |
D/D |
21,473 |
21,494,847 |
0.01 |
- |
|
| Agenus Inc |
|
– – • |
2023-05-03 |
4 |
B |
$1.08 |
$138,843 |
D/D |
128,689 |
21,473,374 |
0.01 |
- |
|
| Armen Garo H |
|
– • – |
2023-05-02 |
4 |
B |
$0.95 |
$94,850 |
D/D |
100,000 |
1,978,010 |
0.01 |
- |
|
| Agenus Inc |
|
– – • |
2023-05-01 |
4/A |
D |
$0.00 |
$0 |
D/D |
(5,006,397) |
21,326,369 |
|
- |
|
| Agenus Inc |
10% Owner |
– – • |
2023-05-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(4,988,273) |
21,344,685 |
|
- |
|
| Baldoni John |
Director |
– • – |
2023-03-01 |
4 |
A |
$2.09 |
$14,375 |
D/D |
6,878 |
23,360 |
|
- |
|
| Wiinberg Ulf |
Director |
– • – |
2023-03-01 |
4 |
A |
$2.09 |
$14,001 |
D/D |
6,699 |
42,751 |
|
- |
|
| Behner Peter |
Director |
– • – |
2023-03-01 |
4 |
A |
$2.09 |
$15,376 |
D/D |
7,357 |
24,985 |
|
- |
|
| Corvese Brian |
Director |
– • – |
2023-03-01 |
4 |
A |
$2.09 |
$17,876 |
D/D |
8,553 |
307,348 |
|
- |
|
| Ryan Barbara |
Director |
– • – |
2023-03-01 |
4 |
A |
$2.09 |
$17,750 |
D/D |
8,493 |
28,844 |
|
- |
|
| Van Dijk Marcus Antonius |
Chief Scientific Officer |
• – – |
2023-01-09 |
4 |
D |
$2.32 |
$56,295 |
D/D |
(24,265) |
27,363 |
|
- |
|
| Van Dijk Marcus Antonius |
Chief Scientific Officer |
• – – |
2023-01-09 |
4 |
A |
$2.32 |
$119,777 |
D/D |
51,628 |
51,628 |
|
- |
|
| Buell Jennifer |
Chief Executive Officer |
• – – |
2023-01-09 |
4 |
A |
$2.32 |
$399,017 |
D/D |
171,990 |
380,715 |
|
- |
|
| Behner Peter |
Director |
– • – |
2022-12-01 |
4 |
A |
$2.61 |
$15,376 |
D/D |
5,891 |
17,628 |
|
- |
|
| Corvese Brian |
Director |
– • – |
2022-12-01 |
4 |
A |
$2.61 |
$17,876 |
D/D |
6,849 |
298,795 |
|
- |
|
| Wiinberg Ulf |
Director |
– • – |
2022-12-01 |
4 |
A |
$2.61 |
$14,000 |
D/D |
5,364 |
36,052 |
|
- |
|
67 Records found
|
|
Page 2 of 3 |
|
|
